EU Approves Subcutaneous Formulation of Ocrelizumab for Multiple Sclerosis Treatment

[BettysMom]

According to a recent announcement, the European Commission (EU) has granted market authorization for a new subcutaneous formulation of ocrelizumab (Ocrevus; Roche), administered twice-yearly as a 10-minute injection for patients with multiple sclerosis (MS). The subcutaneous injection was designed to be administered by healthcare professionals, with the flexibility to administer either in the clinic or in settings outside the clinic.

neurologylive.com/view/eu-a...

[Amore55]

I saw that same information and I am quite intrigued by it. Thanks for sharing it.

[BettysMom in reply to Amore55]

When I posted this I did not know that the subject had already been discussed on this site. However, this is very important news so I think that repeating it may serve a purpose.

[CatsandCars in reply to BettysMom]

Yes, it could really help patients in rural areas access Ocrevus.

[BettysMom in reply to CatsandCars]

And it should make the administration of Ocrevus MUCH less expensive.